A
Aklank Jain
Researcher at Central University of Punjab
Publications - 75
Citations - 2673
Aklank Jain is an academic researcher from Central University of Punjab. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 22, co-authored 55 publications receiving 1664 citations. Previous affiliations of Aklank Jain include University of Texas at Austin & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements.
Vaishali Aggarwal,Hardeep Singh Tuli,Ayşegül Varol,Falak Thakral,Mükerrem Betül Yerer,Katrin Sak,Mehmet Varol,Aklank Jain,Md. Asaduzzaman Khan,Gautam Sethi +9 more
TL;DR: The major issue is targeting the dual actions of ROS effectively with respect to the concentration bias, which needs to be monitored carefully to impede tumor angiogenesis and metastasis for ROS to serve as potential therapeutic targets exogenously/endogenously.
Journal ArticleDOI
DNA triple helices: biological consequences and therapeutic potential.
TL;DR: The biological consequences and therapeutic potential of triple helical DNA structures are discussed and it is anticipated that the information provided will stimulate further investigations aimed toward improving DNA triplex-related gene targeting strategies for biotechnological and potential clinical applications.
Journal ArticleDOI
Molecular Mechanisms of Action of Genistein in Cancer: Recent Advances
Hardeep Singh Tuli,Muobarak J. Tuorkey,Falak Thakral,Katrin Sak,Manoj Kumar,Anil K. Sharma,Uttam Sharma,Aklank Jain,Vaishali Aggarwal,Anupam Bishayee +9 more
TL;DR: Various molecular interactions of genistein with various cellular targets in cancer models covers various molecular mechanisms prevention, treatment, in vivo, in vitro, and clinical studies to help the scientific community understand genisteIn and cancer biology and will provoke them to design novel therapeutic strategies.
Journal ArticleDOI
SNHG12: An LncRNA as a Potential Therapeutic Target and Biomarker for Human Cancer.
Suraksha Tamang,Varnali Acharya,Deepronil Roy,Rinka Sharma,Apeksha Aryaa,Uttam Sharma,Akanksha Khandelwal,Hridayesh Prakash,Karen M. Vasquez,Aklank Jain +9 more
TL;DR: It is proposed that small nucleolar RNA host gene 12 (SNHG12), a lncRNA, may serve as both a biomarker and a druggable therapeutic target with promising clinical potential.
Journal ArticleDOI
Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks.
TL;DR: Electrophoretic mobility-shift assays and chromatin immunoprecipitation analysis of MutSβ and NER proteins with Tdp-ICLs suggest that proteins from the MMR and N ER pathways interact in the recognition of ICLs, and provide a mechanistic link by which proteins from multiple repair pathways contribute to ICL repair.